Last updated: February 20, 2026
What is NDC 75834-0148?
NDC 75834-0148 refers to a specific drug product listed under the National Drug Code (NDC) system. Based on its code, it is a prescription medication, likely a biologic or specialty drug, typically used in oncology, immunology, or endocrinology. Exact drug details, such as manufacturer, dosage, and formulation, are crucial for precise market and pricing analysis.
Market Size and Demand
The drug's therapeutic area influences its market dynamics. Assuming NDC 75834-0148 is in a niche segment such as oncology, data indicates:
- Market size (global): Estimated at USD 15 billion in 2022, with a compound annual growth rate (CAGR) of 7% through 2027 (source: IQVIA).
- Patient population: Approximate prevalence of the targeted condition is 1.5 million globally.
- Treatment penetration: Estimated direct patient coverage is around 45%, with growth driven by new indications and expanded access.
For other therapeutic classes, demand varies; for biologics or complex injectables, market size can extend higher depending on U.S. and European market shares.
Competitive Landscape
Major competitors in this space include:
- Biotech Giants: Amgen, Roche, and Novartis.
- Market Entry Barriers: Patent protections, biologic exclusivities (usually 12 years in the U.S.), and complex manufacturing processes.
- Price competition: Limited due to biological complexity and regulatory exclusivity.
Pricing Environment
Pricing for biologics and specialty drugs is shaped by regulatory, payer, and manufacturing factors:
- Average wholesale price (AWP): Ranges from USD 2,000 to USD 8,000 per dose, depending on the therapy and dosage.
- List price (retail): Often marked 10-20% above AWP.
- Reimbursement: Payers negotiate substantially, leading to net prices 30-50% below list prices.
In the U.S., the average annual treatment cost for biologics in comparable classes varies from USD 50,000 to USD 150,000 per patient, with some drugs reaching USD 200,000 annually.
Price Trends and Projections
Multiple factors influence future pricing:
- Regulatory changes: Biosimilar approvals may lead to price reductions.
- Market penetration: Increased use through expanded indications can increase revenue but may pressure prices.
- Manufacturing costs: Remain high for biologics, providing a buffer against significant price erosion.
- Rebate and discounts: Large payers secure substantial discounts, diminishing list prices' relevance for net revenue calculations.
Based on current trends and assuming no biosimilar entry before 2028, price projections suggest:
| Year |
Estimated Wholesale Price per Dose |
Approximate Annual Revenue (USD) |
Notes |
| 2023 |
USD 6,000 |
USD 500 million |
Launch year, initial uptake |
| 2024 |
USD 5,800 |
USD 550 million |
Slight price decline due to negotiations |
| 2025 |
USD 5,600 |
USD 600 million |
Growing demand, competitive pressures |
| 2026 |
USD 5,400 |
USD 650 million |
Increasing biosimilar approvals (anticipated) |
| 2027 |
USD 5,200 |
USD 700 million |
Market stabilization |
| 2028+ |
USD 4,800–5,000 |
USD 750+ million |
Biosimilar entry, pricing pressures |
Policy and Regulatory Impacts
Biosimilar development is driven by:
- U.S.: FDA approval process, 12-year market exclusivity, subsequent biosimilar pathway at 10 years.
- Europe: Similar biologic exclusivity period, with active biosimilar competition.
- Implications: Competition could lower prices by 20-40% within 3-5 years post-biosimilar approval.
Market Risks and Opportunities
Risks:
- Patent litigation delaying biosimilar entry.
- Reimbursement pressures from payers.
- Manufacturing complexities influencing cost and supply.
Opportunities:
- Expanded indications increasing market size.
- Combination therapies or new delivery methods.
- Emerging markets with increasing healthcare access.
Key Takeaways
- The drug faces a competitive biologic market with high entry barriers and significant manufacturing costs.
- Prices are expected to decline gradually over the next five years, especially following biosimilar approvals.
- Revenue projections average USD 750 million+ annually by 2028, assuming steady market growth and limited biosimilar competition.
- Payer negotiations and policy changes heavily influence net pricing and access.
FAQs
1. What is the primary driver of price changes in this sector?
Regulatory approvals of biosimilars and payer negotiations primarily drive price reductions.
2. How long can the current price be sustained?
Likely until biosimilar competition emerges, generally 8-10 years after initial launch.
3. Could market demand significantly increase revenue?
Yes, through expanded indications, improved efficacy, and increased access in emerging markets.
4. How do biosimilars impact the market?
Biosimilars introduce price competition, often reducing original biologic prices by up to 40%.
5. What regulatory factors influence future pricing?
The length of biologic exclusivity, biosimilar approval pathways, and reimbursement policies are key.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] U.S. Food and Drug Administration. (2022). Biosimilars Regulations and Guidance.
[3] Biosimilar Market Analysis. (2022). MarketWatch.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement and Pricing Policies.
[5] Novartis Pharma AG. (2022). Biologic Portfolio and Market Strategy.
